Global burden of ovarian cancer attributable to high BMI, 1990–2021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study Authors: Jiujie He, Wanting Zhou, Yujun He, Yingjie Nie, Hua Qiu, Wei Mai Published: 2025 ABSTRACT AbstractBackgroundDespite the well-established link between elevated body mass index (BMI) and ovarian cancer, comprehensive global assessments of the attributable burden remain scarce. Using the Global Burden of Disease (GBD) 2021 database, we quantified deaths and disability-adjusted life years (DALYs) from ovarian cancer due to high BMI between 1990 and 2021 and delineated spatiotemporal trends to inform targeted prevention.MethodsWe analyzed GBD 2021 data for 204 countries and territories. Specifically, deaths and DALYs from ovarian cancer attributable to elevated BMI were quantified. Temporal trends were summarized with estimated annual percentage change (EAPC). Trends were examined with Joinpoint, decomposition, frontier, and predictive analyses. ResultsFrom 1990 to 2021, global deaths from ovarian cancer attributable to high BMI rose from 6,850 (95% UI 1,423–12,865) to 17,344 (4,141–30,810), a 153% increase; the age-standardized mortality rate (ASMR) grew by 17% to 0.38 per 100,000 (EAPC 0.40; 95% CI 0.32–0.47). Corresponding DALYs increased from 188,874 (38,401–355,691) to 477,248 (113,449–840,002), pushing the age-standardized DALY rate (ASDR) up 21% to 10.56 per 100,000 (EAPC 0.51; 0.45–0.57). Decomposition showed population growth contributed 57.58% of the net rise in deaths, ageing 25.26% and epidemiological change 17.16%. Only the high-SDI quintile exhibited declining rates; low- and middle-SDI regions sustained increases > 3% per year. Autoregressive Integrated Moving Average (ARIMA) model projections indicate both ASMR and ASDR will continue to climb until 2036.ConclusionsThe BMI-attributable ovarian-cancer burden is rising, particularly among women aged 40–79 years, and urgently requires multisectoral fiscal, screening, and lifestyle interventions tailored to national SDI levels.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13048-025-01917-7.Keywords: Ovarian cancer, High BMI, GBD 2021, Risks factors, Frontier analysis, Predictive analysis Background Ovarian cancer remains the most lethal gynecologic malignancy. Globally, ovarian cancer is the third most commonly diagnosed gynecologic malignancy after endometrial cancer and cervical cancer in 2021 and poses a serious threat to women’s health [1]. Due to its early symptoms being subtle, only 15% of patients are diagnosed at International Federation of Gynecology and Obstetrics (FIGO) stage I-II and achieve good treatment outcomes [2, 3]. However, approximately 70% present with FIGO stage III–IV disease, leading to significant treatment challenges, poor prognosis and overall five-year net survival is approximately 30%, falling below 30% in advanced disease [3, 4]. According to data from the 2021 GBD study, ovarian cancer causes approximately 171,000 deaths and 4.35 million DALYs lost annually in women aged 45 and older [5]. Hence, quantifying modifiable risk factors such as high BMI is essential for targeted prevention strategies. This concern is underscored by a pronounced global rise in obesity. Between 1990 and 2022, the prevalence of obesity among adults has more than doubled. By 2022, approximately 43% of adults were overweight, and 16% were living with obesity, with women generally exhibiting higher prevalence rates than men—a trend particularly pronounced in low- and middle-income countries. Furthermore, overweight and obesity–related mortality and DALYs increase with age and vary by sex [6]. This global trend is of particular concern for ovarian cancer, as ovarian carcinogenesis arises through the cumulative interplay of multiple aetiological factors. Accumulating evidence identifies obesity as a major modifiable determinant of ovarian cancer risk, with BMI demonstrating a dose-dependent positive association with disease incidence [7]. For ovarian cancer, although its relationship with obesity is more complex than that of endometrial cancer, epidemiological evidence consistently identifies elevated BMI as an independent risk factor for the development of ovarian cancer, particularly endometrioid and clear-cell subtypes [8]. Delort et al. reported a significant association between BMI and ovarian cancer risk. This association was more pronounced among premenopausal women than among their postmenopausal counterparts [9]. Individuals in the highest BMI category exhibit an elevated cancer-specific mortality risk compared with those of normal weight [10]. Obesity-driven hyperadiposity, in concert with augmented mitogenic and growth-factor signaling, accelerates tumor progression and confers chemotherapy resistance, ultimately impairing survival outcomes in patients with malignancy [11, 12]. Several well-established biological mechanisms link high BMI to ovarian: increased aromatization of androgens to estradiol in post-menopausal adipose tissue [7, 13], chronic low-grade inflammation (elevated IL-6, TNF-α, CRP) [7], insulin resistance, elevated insulin-like growth factor-1 (IGF-1) levels [14], and dysregulation of adipokine secretion (such as leptin and adiponectin) [7, 13], which collectively constitute the microenvironment for tumorigenesis and development. Consequently, effective management of obesity and its associated metabolic derangements is essential for reducing ovarian cancer incidence and improving patient prognosis. Prior GBD-based studies have advanced ovarian-cancer prevention but remain limited in scope. Zhu Xianglin et al., [15] Chen Guang et al., [16] and Tang WeiZhen et al. [17] conducted a comprehensive analysis of various female tumors to enable an in-depth analysis of ovarian cancer caused by high BMI. Paula Portal Teixeira et al. [18] explored the impact of high fasting blood glucose on tumors, but did not specifically study the burden of high BMI on ovarian cancer. Yanan Ren et al. [5] conducted a study on the disease burden of ovarian cancer in women aged 45 and above, but did not explore risk factors. In addition, none of these studies mentioned cutting-edge analyses of 204 countries and regions worldwide, and there were few separate systematic analyses attributing ovarian cancer to high BMI. Furthermore, there were no overall analyses of the relevant risk factors for ovarian cancer. Therefore, these studies may not accurately reflect current epidemiological changes. This study addresses these gaps by leveraging GBD 2021 data for 204 countries to quantify ovarian-cancer deaths and DALYs attributable to high BMI from 1990 to 2021, characterizing temporal trends with joinpoint regression. We forecast burden to 2036 using ARIMA models and scenario analysis, and apply decomposition analysis to disentangle the contributions of demographic and epidemiological change. Integrating these methods yields a comprehensive evidence base spanning 1990–2036 to inform public-health policy. We systematically quantify deaths and DALYs attributable to high BMI-related ovarian cancer across 204 countries and territories. Consequently, our findings will guide resource allocation and prevention strategies in settings with rising obesity prevalence. Methods Data sources The data for this study are sourced from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 database, which compiles comprehensive epidemiological data from 1990 to 2021 for 371 diseases and injuries across 204 countries and territories [19, 20]. This dataset offers a detailed overview of global disease burden. It includes information from 204 countries and regions. These are grouped into five categories based on their Socio-demographic Index (SDI). The SDI combines average income, education levels, and fertility rates. The categories are low, low-middle, middle, high-middle, and high SDI. The world is also divided into 21 GBD regions. These regions are based on geographical location and similar health patterns. Examples include High-income Asia Pacific and Central Latin America. These 21 regions are then combined into seven larger super-regions, such as the High-income super-region [21, 22]. All estimates are publicly available through the Global Health Data Exchange (GHDx) repository (http://ghdx.healthdata.org/gbd-results-tool). This study examined two primary outcomes—deaths and DALYs—and their age-standardized rates (ASMR, ASDR) and estimated annual percentage changes (EAPCs). The analysis covered 204 countries and territories, assigned to 21 GBD regions defined by epidemiological and socio-demographic criteria, and further stratified into five SDI quintiles. High body mass index (BMI) was defined as a BMI ≥ 25 kg m⁻² for adults (aged 20 years and older), consistent with the exposure threshold used in the GBD 2021 study risk factor analyses [23]. For participants under 20 years of age, we applied the age- and sex-specific cut-offs established by the International Obesity Task Force (IOTF) [24]. BMI was calculated from height and weight measurements taken at baseline, with participants wearing light clothing and no shoes. Ovarian cancer is a group of malignant tumors originating from the ovarian epithelium, germ cells, or stromal cells, with diverse pathological types, including epithelial cancer, germ cell tumors, and sex cord-stromal tumors. Advanced analysis Joinpoint regression analysis We used joinpoint regression to assess temporal trends in ovarian-cancer deaths and DALYs attributable to high BMI. The model sequentially tested H0 (no joinpoint) against H1 (≥ 1 joinpoint) via Monte Carlo permutation at α = 0.05, with model selection based on the Bayesian Information Criterion (BIC). Trend metrics comprised annual percentage change (APC), average annual percentage change (AAPC), and their 95% confidence intervals (CIs) [25–27]. APC denotes the annual percent change estimated under a log-linear model within each segment, whereas AAPC is the weighted average of segment-specific APCs across the entire study period. A 95% uncertainty interval (UI) that excludes 0 denotes a significant upward (UI >0) or downward (UI < 0) trend; a UI spanning 0 indicates no significant change. The SDI analysis The Socio-demographic Index (SDI)—a composite measure of per capita income, education, and fertility—ranges approximately from 0 to 1 [28, 29] and is categorized into five quintiles (low, low-middle, middle, high-middle, high). We assessed the association between age-standardized ovarian-cancer mortality and DALY rates attributable to high BMI and SDI using Pearson correlation after log-transformation [25]. Decomposition analysis We used decomposition analysis to quantify how population growth, aging, and epidemiological change independently affected deaths and the age-standardized DALY rate attributable to high BMI-related ovarian cancer from 1990 to 2021. Population growth drives absolute increases, whereas aging and epidemiological change shape age-standardized rates. The method follows Xie et al. [30, 31]. Frontier analysis Frontier analysis was conducted to compare each country’s observed burden with the minimum achievable burden given its SDI level. This approach helps identify health system inefficiencies and informs resource allocation beyond conventional inequality measures [32, 33]. It should be noted that we did not conduct any quantification of cutting-edge analysis. We only performed a secondary analysis using the GBD 2021 data, and all quantifications and calculations were completed by the Institute for Health Metrics and Evaluation (IHME). Autoregressive integrated moving average (ARIMA) model analysis The ARIMA model, a standard method in time-series forecasting, was used to project global ovarian-cancer deaths and DALYs attributable to high BMI from 2022 to 2036. By modelling the autocorrelation of stationary series [34, 35], the model captures long-term trends and short-term fluctuations. The optimal model was selected with the auto. Arima function based on the lowest Akaike Information Criterion (AIC), and residual white noise was confirmed by the Ljung-Box test (p >0.05) [35, 36]. Risk factors analysis In this study, we report the estimates of ovarian cancer deaths and DALYs attributable to elevated BMI from the GBD 2021 database. It is crucial to note that our analysis constitutes a secondary analysis of publicly available GBD outputs, focusing on the interpretation and stratified examination of these data; the original burden quantification was performed by the Institute for IHME. The estimates were derived using the Comparative Risk Assessment (CRA) framework, which compares observed levels to a Theoretical Minimum Risk Exposure Level (TMREL) [37]. The GBD 2021 implementation of this framework involved a seven-step process: (1) quantifying exposure-specific relative risks; (2) modeling exposure levels using Bayesian tools; (3) establishing the TMREL; (4) calculating population attributable fractions (PAFs); (5) computing summary exposure values (SEVs); (6) adjusting for mediation factors to prevent PAF overestimation; (7) estimating the final attributable burden by age, sex, location, and year. The specific risk attribution methodology employed in this analysis is based on the approach developed by Wang et al. [21, 22] and the GBD 2021 Risk Factors Collaborators [19]. Statistical analysis Statistical analyses and visualizations were performed in R 4.3.3. The joinpoint analysis was performed using the Joinpoint software. The decomposition analysis was conducted employing the dplyr, tidyr, ggplot2, and ggpubr packages in R version 4.3.3. The ARIMA forecasting analysis was conducted utilizing the forecast, dplyr, readr, ggplot2, and ggpubr packages in R version 4.3.3. Descriptive statistics were summarized, and all estimates are presented as with 95% confidence intervals (CIs) or uncertainty intervals (95% UI). For trend analysis, a p-value of less than 0.05 was considered statistically significant. Results Global burden in ovarian cancer burden attributable to high BMI From 1990 to 2021, global deaths attributable to high BMI in ovarian cancer rose from 6850 (95% UI: 1423–12865) to 17,344 (95% UI: 4141–30810), a relative increase of 153%. The ASMR increased from 0.32 (95% UI: 0.07–0.61) to 0.38 (95% UI: 0.09–0.67) per 100,000 women, representing a 17.04% increase over the study period. The EAPC for the ASR of mortality was 0.40 (95% CI: 0.32, 0.47), indicating a modest upward trend (Supplemental Table 1). In terms of DALYs, the global number attributable to high BMI in ovarian cancer cases rose from 188,874 (95% UI: 38401–355691) in 1990 to 477,248 (95% UI: 113449–840002) in 2021, a relative increase of 152.68%. The ASDR increased from 8.72 (95% UI: 1.78–16.41) to 10.56 (95% UI: 2.50 −18.57) per 100,000 women, representing a 21.07% increase over the study period. The EAPC for the ASR of DALYs was 0.51 (95% CI: 0.45, 0.57), indicating a steady upward trend (Supplemental Table 2). Countries and territories burdened by ovarian cancer burden attributable to high BMI The United States recorded the highest numbers of deaths (2,464; 95% UI: 666–4,274) (Fig. 1A), while the United Arab Emirates had highest ASR (3.73; 95% UI: 1.05–6.55) (Supplemental Fig. 1A). Timor-Leste showed the highest EAPC (22.88; 95% CI: 18.77–27.12) (Supplemental Fig. 2A). In the of DALYs, the United States also had the highest burden (58,749; 95% UI: 16,253–101,446) (Fig. 1B), followed by the United Arab Emirates with the highest ASR (80.08; 95% UI: 22.77–140.04) (Supplemental Fig. 1B), and Timor-Leste with the highest EAPC (18.09; 95% UI: 15.96–20.27) (Supplemental Fig. 2B). Detailed country-level results are provided in Supplemental Tables 3 and 4. The case number of deaths and DALYs of ovarian cancer due to high BMI from 1990 to 2021. (A. Deaths; B. DALYs) Results of the trends in ovarian cancer burden attributable to high BMI by year, age and gender From 1990 to 2021, age-specific analyses showed that deaths and DALYs attributable to high BMI in ovarian cancer rose with age worldwide. Globally, the increase was pronounced, whereas trends across the five SDI quintiles were more gradual (Fig. 2). Only the high-SDI quintile exhibited declining ASMR and ASDR, indicating a reduction in BMI-attributable ovarian-cancer burden. All other SDI quintiles and the global aggregate showed upward trends, underscoring a persistent burden (Supplemental Fig. 3). Detailed results for the 21 GBD regions are provided in Supplemental Fig. 4–5. The trends of number in deaths and DALYs for ovarian cancer due to high BMI by global and 5 SDI regions from 1990 to 2021. (A. Deaths; B.DALYs) Across global, five-SDI-quintile, and 21GBD-region perspectives, deaths and DALYs attributable to high BMI-related ovarian cancer exhibited congruent age distributions, peaking at 40–79 years and tapering at younger and older ages. ASMR and ASDR displayed the same age gradient (Supplemental Fig. 6–13). Results of the joinpoint regression analysis for ovarian cancer burden attributable to high BMI Joinpoint regression revealed an overall upward trend in global ovarian-cancer deaths and DALYs attributable to high BMI from 1990 to 2021. AAPC was 0.50 (95% CI:0.36, 0.63) for deaths and 0.61 (95% CI: 0.5, 0.72) for DALYs. Deaths rose steeply from 1990 to 2003, plateaued from 2003 to 2015, and increased again from 2015 to 2021 (Supplemental Tables 5 and Fig. 14 A). DALYs followed a similar pattern (joinpoints 1995, 1999, 2002 and 2015), with modest increases from 1990 to 1995 and 2002–2015 and steeper rises in the remaining intervals (Supplemental Tables 5 and Fig. 14B). Results of the relationship between ovarian cancer burden and SDI attributable to high BMI Globally and across the 21 GBD regions, the relationship between the SDI and ASMR, and ASDR attributable to high BMI-related ovarian cancer was nonlinear. When SDI < 0.75, ovarian-cancer burden rose with SDI; when SDI ≥ 0.75, burden declined. Western Europe and Australasia experienced the steepest declines, whereas other regions showed modest reductions (Fig. 3A-B). Among the 204 countries in 2021, a similar nonlinear relationship existed between SDI and both ASMR and ASDR attributable to high BMI-related ovarian cancer. Compared to countries with an SDI below 0.8, countries with an SDI above 0.8 show a declining trend in the disease burden (Supplemental Fig. 15A-B). SDI analysis results. (A. ASMR; B. ASDR) Results of the decomposition analysis for ovarian cancer attributable to high BMI Decomposition analysis showed that aging contributed + 25.26%, population growth + 57.78%, and epidemiological change + 17.16% to the overall increase in ovarian-cancer deaths. However, epidemiological change reduced the BMI-attributable burden by 12.12% in high SDI region (Fig. 4A and Supplemental Table 6). For DALYs, the same pattern was seen: aging, population growth and epidemiological change contributed + 21.34%, + 57.76% and + 20.9%, respectively. Epidemiological change reduced the burden in the high-SDI 23.24% (Fig. 4B and Supplemental Table 6). Supplemental Fig. 16 and Supplemental Table 6 present the 21 regions decomposition results. Decomposition analysis results across global and 5SDI regions. (A. Deaths; B. DALYs) Frontier analysis of the burden of ovarian cancer burden attributable to high BMI The ASDR increased with SDI (Fig. 5A). Frontier analysis identified 15 countries with the greatest improvement potential: the United Arab Emirates, Bahrain, Seychelles, Latvia, Grenada, Qatar, Georgia, Serbia, Libya, Greenland, Poland, the Russian Federation, Bulgaria, and Trinidad and Tobago. Countries with declining burden from 1990 to 2021 included Lithuania, the United Kingdom, Ireland, Iceland, Monaco, Luxembourg, Canada, the Netherlands, Germany, and Denmark (Fig. 5B). Deaths paralleled DALYs, increasing with SDI. See Supplemental Fig. 16 for details. Frontier analysis involving the SDI and ovarian cancer burden by DALYs. Results of the predictive analysis for ovarian cancer attributable to high BMI The predictive chart shows ASMR and ASDR attributable to high BMI in ovarian cancer from 1990 to 2036, projected to continue its modest upward trajectory (Fig. 6). Specifically, between 1995 and 2000, the disease burden of ovarian cancer in women remained stable, while mortality rates fluctuated significantly compared to DALYs, which remained almost linear. Predictive analysis for ovarian cancer. (A. Deaths; B. DALYs) Discussion This study presents a comprehensive assessment of the global burden of ovarian cancer attributable to high BMI from 1990 to 2021. The observed increases in ASMR (+ 17%) and ASDR (+ 21%) underscore the growing impact of obesity on ovarian cancer outcomes. The absolute burden more than doubled, with deaths rising from 6,850 to 17,344 and DALYs from 188,874 to 477,248. These trends highlight the escalating challenge posed by high BMI, particularly in low- and middle-income regions where age-standardized rates continue to rise. The divergent trends across SDI quintiles—with high-SDI regions showing declining burdens due to improved screening and resource allocation—emphasize the critical role of healthcare infrastructure and public health policies [17, 38]. Our findings are consistent with previous reports [17, 39–41] and provide a robust evidence base for targeted interventions. Substantial heterogeneity in burden was observed across regions and countries, reflecting differences in obesity prevalence, healthcare access, and preventive strategies. The negative EAPC in high SDI regions (−0.36 for deaths, −0.43 for DALYs) contrasted with positive trends exceeding 3.15% in low SDI areas, revealing significant inequalities. This disparity likely stems from differential implementation of evidence-based interventions, such as integrated BMI surveillance, metabolic risk management, and targeted screening programs in high SDI settings [42]. These experiences offer valuable lessons foe low, low-middle and middle SDI regions [17, 40]. The United States recorded the highest absolute burden, driven by its obesity prevalence and healthcare system that often prioritizes treatment over prevention [39, 43]. The disproportionately high BMI-attributable ovarian-cancer burden in the United States and the United Arab Emirates, reflects a convergence of rapid adiposity gains, demographic ageing and health-system priorities. Between 1990 and 2021 the UAE’s age-standardized mean BMI rose by ≈ 1.5 kg m⁻² per decade, twice the global rate [44], while US per-capita curative expenditure exceeded US$ 4,000 yet < 0.3% was allocated to organized ovarian-cancer prevention. Consequently, late-stage presentation (FIGO III/IV >70%) remains common in both countries [45, 46]. Coupled with projected post-menopausal female proportions of 35% by 2030 and low-fertility, high-OCP reproductive patterns, these factors sustain absolute mortality even where surgical capacity is advanced [47, 48]. Effective reversal therefore hinges on structural obesity prevention rather than incremental treatment expansion. The burden was concentrated among women aged 40–79 years, with mortality peaking at 65–69 years and DALYs at 55–59 years. The later mortality peak aligns with advanced-stage diagnosis in older women, where comorbidities complicate treatment and increase case fatality [5, 49, 50]. The earlier DALY peak and subsequent decline after age 65 likely reflect longer survival among younger patients (accumulating more disability years) and increased competing mortality risks in older populations [5]. This age distribution, consistent across all 21 GBD regions [17, 49], underscores the importance of age-specific prevention and early detection initiatives. The nonlinear relationship between SDI and ovarian cancer burden illustrates the epidemiological transition of obesity-related cancers. Increasing burden at SDI levels below 0.75 reflects environmental and lifestyle changes linked to urbanization, including limited healthcare resources and inadequate health literacy [38, 51, 52]. Conversely, when SDI >0.75, burden declines, most notable in high-income Asia Pacific, Australasia and Western Europe. This reduction is driven by multiple factors, including the widespread use of oral contraceptives [38, 53, 54] and risk-reducing surgeries, and hormone-replacement therapy [54–56]. Future prevention strategies should integrate genetic risk assessment, inflammatory biomarkers, and hormonal history to enable personalized approaches, while expanding early interventions targeting adolescent populations. In Australasia, the adult obesity rate remains high at approximately 30%, yet the region has experienced the most pronounced annual decline in ovarian cancer mortality [− 0.96% (−1.36, −0.57) EAPC] and DALYs [− 1.25% (−1.64, −0.87) EAPC] attributable to high BMI. This disparity may be linked to the region’s early implementation of screening policies, oral contraceptive use, and reproductive patterns such as low fertility rates or delayed childbearing [57, 58]. Consequently, the declining disease burden in this region reflects advances in treatment and diagnosis. These data also suggest that without systematic screening, the true carcinogenic impact of obesity could be significantly higher—a critical consideration for middle-SDI countries now entering the steep phase of the obesity transition. Decomposition analysis identified population aging, growth, and epidemiological changes as key drivers of the increasing burden. Aging increases ovarian cancer risk through accumulated mutagenesis (including BRCA1/2 pathways) and post-menopausal hormonal changes, while population growth raises absolute case numbers [5, 61]. Changing reproductive patterns and rising metabolic disease prevalence further elevate risk [62, 63], with healthcare disparities and diagnostic delays exacerbating these trends [5, 59, 64, 65]. Comprehensive strategies integrating risk-stratified screening, lifestyle modification, and precision therapy are essential to address this multifactorial challenge. Frontier analysis indicated that ASMR and ASDR increase with SDI, reflecting the dual burden of Western lifestyles (e.g., high obesity, physical inactivity, and reproductive pattern changes) in high SDI regions and competing health priorities (e.g., infectious diseases, malnutrition) in low SDI areas. Predictive modeling suggests a continued global increase in BMI-attributable burden, necessitating immediate, tiered responses: high-SDI regions should implement structural interventions (e.g., sugar taxes, marketing regulations) and optimize healthcare, while low SDI regions require international support to strengthen diagnostic capacity, cancer registration, and preventive policies addressing dietary transitions. The pathophysiological mechanisms linking high BMI to ovarian cancer involve interconnected metabolic pathways, including adipokine profile alterations, insulin resistance, chronic inflammation [7, 66], and energy-metabolism reprogramming through enhanced glycolysis and mitochondrial dysfunction [67, 68]. For metabolic risks, population-level interventions should include evidence-based nutrition education, multisectoral food policies, and environmental modifications promoting healthy diets. Enhanced primary prevention and periodic health surveillance for high-risk groups are also essential. Despite its comprehensive approach, this study has several limitations. First, heterogeneous data sources and variable quality across regions introduce uncertainty, particularly for resource-limited settings [69, 70]. Second, the SDI framework may mask within-country heterogeneity by standardizing education, income, and fertility metrics. Third, risk-attribution models rely on indirect exposure-response functions, which may underestimate the true burden [38, 71]. Finally, GBD indicators do not fully capture nuanced dietary patterns, healthcare-seeking behaviors, or broader cultural determinants of health. Future studies should leverage digital health technologies and advanced analytics to improve data collection and risk estimation models. Conclusions This systematic analysis demonstrates the substantial and growing global burden of ovarian cancer attributable to high BMI, with pronounced disparities across regions, ages, and SDI levels. Our findings highlight the urgent need for tailored interventions addressing metabolic risk factors through coordinated public health strategies. Future efforts should focus on integrating personalized prevention approaches while strengthening surveillance systems to monitor progress and evaluate interventions. Supplementary Information Supplementary material 1. Acknowledgements Not applicable. Abbreviations body-mass index Global Burden of Disease disability-adjusted life-years age-standardized mortality rate age-standardized DALYs rate estimated annual percentage change Socio-demographic Index Guidelines for Accurate and Transparent Health Estimates Reporting Autoregressive Integrated Moving Average International Federation of Gynecology and Obstetrics Institute for Health Metrics and Evaluation Comparative Risk Assessment Theoretical Minimum Risk Exposure Level population attributable fractions summary exposure values Authors’ contributions Jiujie He: Writing-original draft, Writing-review & editing, Conceptualization, Methodology, Formal analysis, Data curation, Supervision, Funding acquisition.Wanting Zhou: Writing-review & editing, Investigation, Data curation, Validation.Yujun He: Writing-review & editing, Conceptualization, Visualization.Yingjie Nie: Writing-review & editing, Formal analysis, Data curation.Hua Qiu: Writing-review & editing, Project administration, Funding acquisition.Wei Mai: Writing-review & editing, Methodology, Data curation, Funding acquisition, Project administration, Supervision. Funding The research was supported by: (1) Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation under Grant (No. 2024GXNSFBA010165); (2) Project of the Universal Support Policy for the First Batch of Young Talent “Qingmiao” Program in Guangxi Zhuang Autonomous Region (No.2024-2); (3) This research was supported by Youth Program of Scientific Research Foundation of Guangxi Medical University Cancer Hospital (No.2023-9); (4) Youth Fund of Guangxi Medical University (No. GXMUYSF202445); (5) Excellent Doctoral Funding Project of Guangxi Medical University Cancer Hospital (No.2023-1); (6) Guangxi Zhuang Autonomous Region Engineering Research Center for the Development and Application of Snake-Based Anticancer Medicines [Guangxi Development and Reform Commission High-Tech Letter (2023) No. 2727]; (7) Guangxi Key Laboratory for the Prevention and Treatment of Regionally Prevalent Cancers Using Traditional Chinese Medicine (Guangxi Traditional Chinese Medicine Science and Education Development [2023] No. 9); (8) Self-funded scientific research project of the Guangxi Zhuang Autonomous Region Administration of Traditional Chinese Medicine (No. GXZYA20240358). Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Not applicable. Competing interests The authors declare no competing interests. Conflict of interest The authors declare that the study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Not applicable. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary material 1. Data Availability Statement No datasets were generated or analysed during the current study.